Sorafenib and sunitinib

Oncologist. 2009 Aug;14(8):800-5. doi: 10.1634/theoncologist.2009-0088. Epub 2009 Aug 1.
No abstract available

Publication types

  • Research Support, N.I.H., Intramural
  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacokinetics*
  • Antineoplastic Agents / therapeutic use*
  • Benzenesulfonates / adverse effects
  • Benzenesulfonates / chemistry
  • Benzenesulfonates / pharmacokinetics*
  • Benzenesulfonates / therapeutic use*
  • Drug Interactions
  • Humans
  • Indoles / adverse effects
  • Indoles / chemistry
  • Indoles / pharmacokinetics*
  • Indoles / therapeutic use*
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / adverse effects
  • Pyridines / chemistry
  • Pyridines / pharmacokinetics*
  • Pyridines / therapeutic use*
  • Pyrroles / adverse effects
  • Pyrroles / chemistry
  • Pyrroles / pharmacokinetics*
  • Pyrroles / therapeutic use*
  • Sorafenib
  • Sunitinib

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Indoles
  • Phenylurea Compounds
  • Pyridines
  • Pyrroles
  • Niacinamide
  • Sorafenib
  • Sunitinib